Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer. (2019)

Peer-Reviewed Study · Le Zhang; Milana Bochkur Dratver; Taha Yazal et al. · January 1, 2019

Le Zhang et al., 2019-01-01: Zhang et al. show mebendazole prevents radiation-induced conversion of triple-negative breast cancer cells into cancer-initiating cells and delays xenograft growth with radiation at the higher dose tested.

The combination of 10 Gy with 10 mg/kg of MBZ did not have any added effect on tumor growth compared with 10 Gy alone (Fig. 3C, solid triangles vs empty circles).

Le Zhang et al., 2019-01-01: Zhang et al. show mebendazole prevents radiation-induced conversion of triple-negative breast cancer cells into cancer-initiating cells and delays xenograft growth with radiation at the higher dose tested. Study type: TNBC cell lines plus a SUM159PT subcutaneous xenograft. N: not stated in the abstract; groups of mice per arm. Country: USA (UCLA). Dose: 10 mg/kg or 20 mg/kg, 5 days on/2 days off for 3 weeks, with a single 10 Gy dose. Funder: US NIH P50 CA211015 and R01 CA161294. Declared conflicts: 'Conflict of interest: none.' Comparator: radiation alone and vehicle. PARTLY because the lower dose added nothing to radiation; only 20 mg/kg delayed growth beyond radiation alone. Study type: animal.